Chemical Compound Review:
AC1O745K 2-[ (3S,5S,6R,7S,8E,10R,11R,12Z,14 E)-6...
Synonyms:
Ochel,
Gademann,
Ramanathan,
Trump,
Eiseman,
Belani,
Agarwala,
Zuhowski,
Lan,
Potter,
Ivy,
Ramalingam,
Brufsky,
Wong,
Tutchko,
Egorin,
Egorin,
Lagattuta,
Hamburger,
Covey,
White,
Musser,
Eiseman,
Eiseman,
Lan,
Lagattuta,
Hamburger,
Joseph,
Covey,
Egorin,
Ramanathan,
Egorin,
Eiseman,
Ramalingam,
Friedland,
Agarwala,
Ivy,
Potter,
Chatta,
Zuhowski,
Stoller,
Naret,
Guo,
Belani,
- Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Ramanathan, R.K., Egorin, M.J., Eiseman, J.L., Ramalingam, S., Friedland, D., Agarwala, S.S., Ivy, S.P., Potter, D.M., Chatta, G., Zuhowski, E.G., Stoller, R.G., Naret, C., Guo, J., Belani, C.P. Clin. Cancer Res. (2007)
- A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Ronnen, E.A., Kondagunta, G.V., Ishill, N., Sweeney, S.M., Deluca, J.K., Schwartz, L., Bacik, J., Motzer, R.J. Investigational new drugs. (2006)
- 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Burger, A.M., Fiebig, H.H., Stinson, S.F., Sausville, E.A. Anticancer Drugs (2004)
- In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation. Ochel, H.J., Gademann, G. Anticancer Res. (2006)
- Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Ramanathan, R.K., Trump, D.L., Eiseman, J.L., Belani, C.P., Agarwala, S.S., Zuhowski, E.G., Lan, J., Potter, D.M., Ivy, S.P., Ramalingam, S., Brufsky, A.M., Wong, M.K., Tutchko, S., Egorin, M.J. Clin. Cancer Res. (2005)
- Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Egorin, M.J., Lagattuta, T.F., Hamburger, D.R., Covey, J.M., White, K.D., Musser, S.M., Eiseman, J.L. Cancer Chemother. Pharmacol. (2002)
- Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Egorin, M.J., Zuhowski, E.G., Rosen, D.M., Sentz, D.L., Covey, J.M., Eiseman, J.L. Cancer Chemother. Pharmacol. (2001)
- Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor-bearing mice. Xu, L., Eiseman, J.L., Egorin, M.J., D'Argenio, D.Z. Journal of pharmacokinetics and pharmacodynamics. (2003)
- Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. Agnew, E.B., Wilson, R.H., Grem, J.L., Neckers, L., Bi, D., Takimoto, C.H. J. Chromatogr. B Biomed. Sci. Appl. (2001)
- Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Eiseman, J.L., Lan, J., Lagattuta, T.F., Hamburger, D.R., Joseph, E., Covey, J.M., Egorin, M.J. Cancer Chemother. Pharmacol. (2005)